Literature DB >> 34252866

Artificial intelligence to assess body composition on routine abdominal CT scans and predict mortality in pancreatic cancer- A recipe for your local application.

Tzu-Ming Harry Hsu1, Khoschy Schawkat2, Seth J Berkowitz3, Jesse L Wei3, Alina Makoyeva3, Kaila Legare3, Corinne DeCicco4, S Nicolas Paez3, Jim S H Wu3, Peter Szolovits1, Ron Kikinis5, Arthur J Moser4, Alexander Goehler6.   

Abstract

BACKGROUND: Body composition is associated with mortality; however its routine assessment is too time-consuming.
PURPOSE: To demonstrate the value of artificial intelligence (AI) to extract body composition measures from routine studies, we aimed to develop a fully automated AI approach to measure fat and muscles masses, to validate its clinical discriminatory value, and to provide the code, training data and workflow solutions to facilitate its integration into local practice.
METHODS: We developed a neural network that quantified the tissue components at the L3 vertebral body level using data from the Liver Tumor Challenge (LiTS) and a pancreatic cancer cohort. We classified sarcopenia using accepted skeletal muscle index cut-offs and visceral fat based its median value. We used Kaplan Meier curves and Cox regression analysis to assess the association between these measures and mortality.
RESULTS: Applying the algorithm trained on LiTS data to the local cohort yielded good agreement [>0.8 intraclass correlation (ICC)]; when trained on both datasets, it had excellent agreement (>0.9 ICC). The pancreatic cancer cohort had 136 patients (mean age: 67 ± 11 years; 54% women); 15% had sarcopenia; mean visceral fat was 142 cm2. Concurrent with prior research, we found a significant association between sarcopenia and mortality [mean survival of 15 ± 12 vs. 22 ± 12 (p < 0.05), adjusted HR of 1.58 (95% CI: 1.03-3.33)] but no association between visceral fat and mortality. The detector analysis took 1 ± 0.5 s.
CONCLUSIONS: AI body composition analysis can provide meaningful imaging biomarkers from routine exams demonstrating AI's ability to further enhance the clinical value of radiology reports.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Artificial intelligence; Body composition; CT scans; Deep learning; Patient risk stratification

Year:  2021        PMID: 34252866     DOI: 10.1016/j.ejrad.2021.109834

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  5 in total

1.  Deep-learning-based Segmentation of Skeletal Muscle Mass in Routine Abdominal CT Scans.

Authors:  Robert Kreher; Mattes Hinnerichs; Bernhard Preim; Sylvia Saalfeld; Alexey Surov
Journal:  In Vivo       Date:  2022 Jul-Aug       Impact factor: 2.406

2.  Influence of Baseline CT Body Composition Parameters on Survival in Patients with Pancreatic Adenocarcinoma.

Authors:  Nick Lasse Beetz; Dominik Geisel; Christoph Maier; Timo Alexander Auer; Seyd Shnayien; Thomas Malinka; Christopher Claudius Maximilian Neumann; Uwe Pelzer; Uli Fehrenbach
Journal:  J Clin Med       Date:  2022-04-22       Impact factor: 4.964

Review 3.  The Value of Artificial Intelligence-Assisted Imaging in Identifying Diagnostic Markers of Sarcopenia in Patients with Cancer.

Authors:  Ying-Tzu Huang; Yi-Shan Tsai; Peng-Chan Lin; Yu-Min Yeh; Ya-Ting Hsu; Pei-Ying Wu; Meng-Ru Shen
Journal:  Dis Markers       Date:  2022-03-29       Impact factor: 3.434

Review 4.  Application of artificial intelligence to pancreatic adenocarcinoma.

Authors:  Xi Chen; Ruibiao Fu; Qian Shao; Yan Chen; Qinghuang Ye; Sheng Li; Xiongxiong He; Jinhui Zhu
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

5.  Visceral Adiposity and Severe COVID-19 Disease: Application of an Artificial Intelligence Algorithm to Improve Clinical Risk Prediction.

Authors:  Alexander Goehler; Tzu-Ming Harry Hsu; Jacqueline A Seiglie; Mark J Siedner; Janet Lo; Virginia Triant; John Hsu; Andrea Foulkes; Ingrid Bassett; Ramin Khorasani; Deborah J Wexler; Peter Szolovits; James B Meigs; Jennifer Manne-Goehler
Journal:  Open Forum Infect Dis       Date:  2021-05-28       Impact factor: 3.835

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.